Novo bets on Triple G obesity drug in up to $2 bn deal with Chinese biotech
Novo has been trying to strengthen its foothold in the potential $150 billion obesity market through the development of ...
Novo licenses Chinese biotech's obesity drug candidate for up to $2 billion
(Reuters) -Danish drugmaker Novo Nordisk has secured the global rights to develop, manufacture and sell China-based United ...
MT Newswires on MSN59m
Novo Nordisk Strikes Up to $2 Billion Licensing Deal for Chinese Firm's Obesity, Diabetes Drug Candidate
Novo Nordisk (NVO) secured exclusive global rights to United Laboratories International's therapeutic candidate for obesity and type 2 diabetes in a licensing deal worth up to $2 billion. The product ...